Individualized Medicine Biobank for Mitochondrial Diseases
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 09-002265
Sponsor Protocol Number: 09-002265
About this study
The Mitochondrial Disease Biobank is a place to store blood and tissue samples from people with symptoms of mitochondrial disease. Health information about each donor will be attached to the samples.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Age birth-100 years, male or female, any race/ethnicity
- Potential participant shall have a confirmed diagnosis of a mitochondrial disease or a suspected diagnosis based on a review of clinical history by a Mitochondrial Disease Biobank working group member using the clinical criteria listed in the table below
- Selected participants shall have at least two documented conditions contained within the minor clinical criteria
- Minor Criteria
- Symptoms compatible with a mitochondrial defect
- Smaller numbers of RRF or widespread electron microscopy abnormalities of mitochondria
- Antibody-based demonstration of an mito defect or residual activity of an mito complex 20%–30% in a tissue, 30%–40% in a cell line, or 30%–40% in >2 tissues
- Fibroblast ATP synthesis rates 2–3 SD below mean, or fibroblasts unable to grow in galactose media
- Nuclear or mtDNA mutation of probable pathogenicity
- One or more metabolic indicators of impaired metabolic function
- OR one condition in the major criteria with evidence of a condition in the minor criteria, will be considered for inclusion of a participant of appropriate age
- Major Criteria
- Multi-systemic symptoms characteristic of mito disorder
- Progressive clinical course with episodes of exacerbation
- A family history strongly indicative of an mtDNA mutation
- Exclusion of other metabolic or non-metabolic disorders
- >2% ragged red fibers (RRF) in skeletal muscle
- Cytochrome c oxidase negative fibers (>2-5%) or residual activity of a mito complex <20% in a tissue; <30% in a cell line, or <30% in >2 tissues
- Fibroblast ATP synthesis rates >3 SD below mean
- Nuclear or mtDNA mutation of undisputed pathogenicity
- 1st-degree relatives of affected participants (described above) are also invited to participate in the project.
- In addition, samples from participants with one of the following mitochondrial disease diagnosis will be included:
- Alpers’ progressive sclerosing poliodystrophy
- Barth syndrome
- CPEO
- Dominant optic atrophy
- Friedriech’s Ataxia
- Hereditary paraganglioma
- Hereditary spastic paraplegia
- Kearns-Sayre syndrome Leber hereditary optic neuroretinopathy
- Leigh and Leigh-like Syndrome
- MELAS
- MERRF
- NARP
- Pearson syndrome
- Wolfram syndrome
- Mitochondrial fatty acid oxidation disorder
- Urea cycle defect
Exclusion Criteria:
- Unwilling to provide informed consent
- Unwilling to consent to providing biospecimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design
- Does not have a diagnosis of mitochondrial disease or clinical symptoms that are indicative of a potential mitochondrial disease as determined by a chart review by at least one Individualized Medine Biobank for Mitochondrial Disease working-group member
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Devin Oglesbee, Ph.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available